J. B. Chemicals & Pharmaceuticals Limited
NSE: JBCHEPHARMMarket Closed • NSE
Day range
52 week range
J. B. Chemicals & Pharmaceuticals Limited closed at INR2416.10 (+0.3%) on volume 7.72x its 20-day average, trading 4.33% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved -48.8% QoQ
2026-05-29
DIVIDEND Announced
Dividend - Rs 9.30 Per Share
2026-02-11
DIVIDEND Announced
Interim Dividend - Rs 12.70 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.09x
High Cash Flow Conversion: CFO/PAT averaged 1.17x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 54.2x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 29 May 2026 | Dividend | ₹9.30 / share | — | 29 May 2026 |
| 11 Feb 2026 | Dividend | ₹12.70 / share | — | 11 Feb 2026 |
| 30 Jul 2025 | Dividend | ₹7.00 / share | — | 30 Jul 2025 |
| 08 Feb 2025 | Dividend | ₹8.50 / share | — | 07 Feb 2025 |
| 14 Aug 2024 | Dividend | ₹6.75 / share | — | 14 Aug 2024 |
| 16 Feb 2024 | Dividend | ₹5.50 / share | — | 16 Feb 2024 |
| 18 Sept 2023 | Dividend | ₹2.00 / share | — | 18 Sept 2023 |
| 17 Aug 2023 | Dividend | ₹9.25 / share | — | 17 Aug 2023 |
| 18 Feb 2023 | Dividend | ₹8.50 / share | — | 17 Feb 2023 |
| 17 Aug 2022 | Dividend | ₹8.00 / share | — | 12 Aug 2022 |
| 24 Feb 2022 | Dividend | ₹8.50 / share | — | 23 Feb 2022 |
| 02 Sept 2021 | Dividend | ₹8.00 / share | — | 01 Sept 2021 |
| 22 Feb 2021 | Dividend | ₹8.50 / share | — | 18 Feb 2021 |
| 23 Sept 2020 | Dividend | ₹1.00 / share | — | 22 Sept 2020 |
| 04 Mar 2020 | Dividend | ₹10.00 / share | — | 03 Mar 2020 |
| 22 Nov 2019 | Buyback | Buyback | — | 21 Nov 2019 |
| 16 Aug 2019 | Dividend | ₹5.00 / share | — | 14 Aug 2019 |
| 12 Sept 2018 | Buyback | Buyback | — | 11 Sept 2018 |
| — | Dividend | ₹2.00 / share | — | 27 Aug 2018 |
| — | Dividend | ₹1.00 / share | — | 11 Sept 2017 |
| 02 Jun 2017 | Buyback | Buyback | — | 01 Jun 2017 |
| — | Dividend | ₹0.50 / share | — | 11 Aug 2016 |
| 19 Mar 2016 | Dividend | ₹4.50 / share | — | 17 Mar 2016 |
| — | Dividend | ₹4.00 / share | — | 06 Aug 2015 |
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.
IndiaHealthcare
Is J. B. Chemicals & Pharmaceuticals Limited Shariah compliant?
J. B. Chemicals & Pharmaceuticals Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (0.01%) complies with AAOIFI threshold (≤ 33%).
What is J. B. Chemicals & Pharmaceuticals Limited's current valuation relative to peers?
J. B. Chemicals & Pharmaceuticals Limited trades at a P/E of 54.2x compared to the sector median of 37x, and a Price-to-Book of 9.3x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.09x. Interest coverage is 165.6x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 3.4% while net profit growth averaged 5.1%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-07-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.